ClinicalTrials.gg
RecruitingNCT05683418Updated Nov 17, 2026

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

A Phase 1 interventional study of TOS-358 and Fulvestrant in HR+/HER2-negative Breast Cancer, sponsored by Totus Medicines. Recruiting at 25 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Totus Medicines · Phase 1, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.
Updated Nov 17, 2026Site recruiting status changed7 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
241
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria. The main questions it aims to answer are:

  1. Phase 1a: what is the maximum tolerated dose and recommended dose for phase 2?
  2. Phase 1a: how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day?
  3. Phase 1b: how safe and effective is TOS-358 when given with standard of care medicines for HR+HER2- metastatic breast cancer (fulvestrant and CDK4/6i)
Read the detailed description

This study will be conducted in two parts: a dose finding portion to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) of TOS-358 administered orally on once a day (QD) and twice daily (BID) schedules, and a dose expansion portion to evaluate safety and tolerability in tumor-specific cohorts administered TOS-358 at the recommended phase 2 dose and schedule.

Women with histologically confirmed diagnosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer with known PIK3CA mutations or amplifications and who meet all of the eligibility criteria will be enrolled in the study.

In the dose finding portion of the study, TOS-358 will be evaluated as a single-agent at multiple dose levels administered orally until disease progression, unacceptable toxicity, or until meeting any other reason for discontinuation as specified in the protocol. In the Phase 1b portion, TOS-358 will be combined with fulvestrant +/- CDK4/6i.

02

Conditions studied

  • HR+/HER2-negative Breast Cancer

Browse trials for

Keywords

  • PI3K-alpha
  • breast cancer
  • metastatic breast cancer
  • PIK3CA
  • hormone receptor positive breast cancer
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 241 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

This is the only study on the registry with Totus Medicines as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Locally advanced, recurrent, or HR +/- breast cancer
  • Up to 3 for metastatic disease
  • Willing and able to provide written for this study
  • Adults ≥ 18 years old at time of consent
  • Known PIK3CA mutations or amplifications as determined at a CAP/CLIA-certified or equivalently accredited diagnostic laboratory using a validated test
  • Measurable or evaluable disease by 1.1
  • (ECOG) performance status of 0 or 1
  • ≥ 6 months, as determined by the investigator
  • Adequate bone marrow, liver, and kidney function within 14 days prior to first dose of product
  • Fasting plasma glucose \<= 140 mg/dL AND (HbA1c) \<= 7.0%
  • Available archived or fresh tumor tissue sample for detection of PIK3CA mutation by central laboratory test

Key Exclusion Criteria

  • Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2
  • Known active central nervous system (CNS) metastases
  • PTEN mutations
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
241 participants (estimated)

Study arms

  • Experimental
    TOS-358 + fulvestrant

    TOS-358 + fulvestrant at standard dosing

    Drug: TOS-358 · Drug: Fulvestrant

  • Experimental
    TOS-358 + fulvestrant + CDK4/6i

    TOS-358 + fulvestrant + CDK4/6i

    Drug: TOS-358 · Drug: Fulvestrant · Drug: Palbociclib · Drug: Ribociclib

  • Experimental
    TOS-358

    PIK3CA covalent inhibitor

    Drug: TOS-358

Interventions

  • DrugTOS-358

    Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor

  • Intramuscular SERD at standard doses

  • CDK4/6 inhibitor at standard doses

  • CDK4/6 inhibitor at standard doses

06

What researchers measure

Primary outcomes

  1. Determine the rate of dose-limiting toxicities (DLTs)

    Time frame: First 21 days of treatment

  2. Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5

    Time frame: Start of treatment to 30 days after last dose

Secondary outcomes

  1. ORR and duration of tumor control

    Measures of efficacy of TOS-358 monotherapy and in combination with standard of care treatment in early line metastatic HR+HER2- breast cancer

    Time frame: Up to 24 months

07

Study locations

15 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 58 months is above that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2022
First posted
Jan 13, 2023
StartActual
Feb 15, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added. 7 sites changed recruiting status (7 now terminated)
Show 7 sites
  • Beth Israel Deaconess Medical Center · Boston, United StatesRecruiting→Terminated
  • Comprehensive Cancer Centers of Nevada · Las Vegas, United StatesRecruiting→Terminated
  • University of Pennsylvania · Philadelphia, United StatesRecruiting→Terminated
  • Virginia Cancer Specialists · Fairfax, United StatesRecruiting→Terminated
  • START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS · Madrid, SpainRecruiting→Terminated
  • Clinica Universidad de Navarra · Pamplona, SpainRecruiting→Terminated
  • NEXT Oncology - Hospital Quironsalud Madrid - PPDS · Pozuelo de Alarcón, SpainRecruiting→Terminated
Show 7 added (7 United States)
  • University of Southern California Cancer Center · Los Angeles, United States
  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center · San Francisco, United States
  • Florida Cancer Specialists & Research Institute · St. Petersburg, United States
  • Maryland Oncology Hematology Cancer Specialists · Calverton, United States
  • Compass Oncology West Cancer Center · Tigard, United States
  • MD Anderson Cancer Center · Houston, United States
  • Blue Ridge Cancer Care · Roanoke, United States
Nov 17, 2026
Site contacts
Changed at 8 sites. See the sites
Show 8 sites
  • Beth Israel Deaconess Medical Center · Boston, United StatesContact removed v•••@bidmc.harvard.edu · •••7489Contact removed g•••@bidmc.harvard.eduContact removed (no phone or email listed)
  • Comprehensive Cancer Centers of Nevada · Las Vegas, United StatesContact removed a•••@usoncology.com · •••3406Contact removed E•••@usoncology.comContact removed (no phone or email listed)
  • University of Pennsylvania · Philadelphia, United StatesContact removed A•••@pennmedicine.upenn.edu · •••6292Contact removed P•••@uphs.upenn.eduContact removed (no phone or email listed)
  • Vanderbilt-Ingram Cancer Center · Nashville, United StatesContact •••8480→•••8480
  • Virginia Cancer Specialists · Fairfax, United StatesContact removed a•••@usoncology.com · •••1473Contact removed L•••@usoncology.com · •••9396
  • START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS · Madrid, SpainContact removed b•••@startmadrid.com · •••4800Contact removed (no phone or email listed)
  • Clinica Universidad de Navarra · Pamplona, SpainContact removed j•••@unav.es · •••5400Contact removed (no phone or email listed)
  • NEXT Oncology - Hospital Quironsalud Madrid - PPDS · Pozuelo de Alarcón, SpainContact removed v•••@nextoncology.eu · •••1900Contact removed (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    7 sites added. 7 sites changed recruiting status (7 now terminated)
    Show 7 sites
    • Beth Israel Deaconess Medical Center · Boston, United StatesRecruiting→Terminated
    • Comprehensive Cancer Centers of Nevada · Las Vegas, United StatesRecruiting→Terminated
    • University of Pennsylvania · Philadelphia, United StatesRecruiting→Terminated
    • Virginia Cancer Specialists · Fairfax, United StatesRecruiting→Terminated
    • START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS · Madrid, SpainRecruiting→Terminated
    • Clinica Universidad de Navarra · Pamplona, SpainRecruiting→Terminated
    • NEXT Oncology - Hospital Quironsalud Madrid - PPDS · Pozuelo de Alarcón, SpainRecruiting→Terminated
    Show 7 added (7 United States)
    • University of Southern California Cancer Center · Los Angeles, United States
    • University of California San Francisco Helen Diller Family Comprehensive Cancer Center · San Francisco, United States
    • Florida Cancer Specialists & Research Institute · St. Petersburg, United States
    • Maryland Oncology Hematology Cancer Specialists · Calverton, United States
    • Compass Oncology West Cancer Center · Tigard, United States
    • MD Anderson Cancer Center · Houston, United States
    • Blue Ridge Cancer Care · Roanoke, United States
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • Beth Israel Deaconess Medical Center · Boston, United StatesContact removed v•••@bidmc.harvard.edu · •••7489Contact removed g•••@bidmc.harvard.eduContact removed (no phone or email listed)
    • Comprehensive Cancer Centers of Nevada · Las Vegas, United StatesContact removed a•••@usoncology.com · •••3406Contact removed E•••@usoncology.comContact removed (no phone or email listed)
    • University of Pennsylvania · Philadelphia, United StatesContact removed A•••@pennmedicine.upenn.edu · •••6292Contact removed P•••@uphs.upenn.eduContact removed (no phone or email listed)
    • Vanderbilt-Ingram Cancer Center · Nashville, United StatesContact •••8480→•••8480
    • Virginia Cancer Specialists · Fairfax, United StatesContact removed a•••@usoncology.com · •••1473Contact removed L•••@usoncology.com · •••9396
    • START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS · Madrid, SpainContact removed b•••@startmadrid.com · •••4800Contact removed (no phone or email listed)
    • Clinica Universidad de Navarra · Pamplona, SpainContact removed j•••@unav.es · •••5400Contact removed (no phone or email listed)
    • NEXT Oncology - Hospital Quironsalud Madrid - PPDS · Pozuelo de Alarcón, SpainContact removed v•••@nextoncology.eu · •••1900Contact removed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05683418
Lead sponsor
Totus Medicines
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Feb 15, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Clinical Trials
Contact
clinicaltrials@totusmedicines.com
Please e-mail
Zelanna Goldberg, MD
study director · Totus Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion